STAT3 and familial pancreatic carcinoma: Moreover, results in this experiment show remarkable synergistic effects observed in pancreatic cancer cells treated with selective STAT3 inhibitors, an EGFR/ErbB2 inhibitor, and a HIF-1α inhibitor.